What You Need to Know About Biogen's Blockbuster

Today, Fool.com health-care analysts David Williamson and Max Macaluso look at what investors need to know about Biogen's potential blockbuster drug BG-12.

It looks as if investors will have to wait a little longer, as the drug has been delayed. Shares are down only moderately on the news, and investors really shouldn't be too worried. David explains why this isn't as bad as it seems, and why this drug could still be one of the biggest blockbusters ever.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article What You Need to Know About Biogen's Blockbuster originally appeared on Fool.com.

David Williamson, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Biogen Idec. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.